Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what potential new treatments for glioblastoma have been trialled in the NHS.

The Department of Health and Social Care enables research via its research arm, the National Institute for Health and Care Research (NIHR), and is committed to furthering our investment and driving scientific advancements in research into the causes and treatment of brain tumours. Between 2018/19 and 2023/24, the NIHR directly invested £11.8 million via research programmes and training. UK Research and Innovation, funded by the Department for Science, Innovation and Technology, invested £46.8 million.

During the same period, the NIHR’s wider investments of approximately £37.5 million in research infrastructure and the research workforce have enabled the delivery of an additional 261 brain tumour research studies, allowing over 11,400 more people to participate in brain tumour research. NIHR infrastructure provides world-class research expertise, specialist facilities, a research delivery workforce, and support services to enable and deliver research across the National Health Service and wider health and care system.

For example, the CITADEL-123 trial, supported by the NIHR’s University College London Hospital (UCLH) Clinical Research Facility and the UCLH Biomedical Research Centre, is trialling the use of resection surgery followed by implantation of a medical device which delivers radioactive therapy in patients with recurrent glioblastoma. A separate trial of a drug derived from olive oil has shown promise in early studies for patients with glioblastoma. The NIHR Biomedical Research Centre at the Royal Marsden and the Institute of Cancer Research and Experimental Cancer Medicine Centre Network, which the NIHR jointly funds, support the work of the Drug Development Unit, which supported the study.

The Win-Glio trial, also supported by the NIHR’s UCLH Clinical Research Facility, is testing immunotherapy treatment using the drug ipilimumab prior to standard treatment in patients with glioblastoma.

The NIHR continues to welcome funding applications for research into any aspect of human health and care, including glioblastoma. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to the public and health and care services, value for money, and scientific quality.